Avalon GloboCare Corp 2025年季度报告

Item 1. Financial StatementsCondensed Consolidated Balance Sheets – At March 31, 2025 (Unaudited) and December 31, 2024Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) – For the Three Months Item 4. Mine Safety Disclosures Item 5. Other Information NET CASH USED IN OPERATING ACTIVITIES Proceeds from sale of equity method investment NET CASH PROVIDED BY INVESTING ACTIVITIES Proceeds from issuance of convertible debt and warrants-Payments of convertible debt issuance costs-Repayments of convertible debt-Advance from pending sale of noncontrolling interest in subsidiary219,9721,210,472 NET CASH PROVIDED BY FINANCING ACTIVITIES219,972EFFECT OF EXCHANGE RATE ON CASH231NET (DECREASE) INCREASE IN CASH(1,486,723) CASH - end of period$1,369,586$SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:Cash paid for:Interest Settlement of derivative liability$18,853$Issuance of common stock upon cashless exercise of stock warrants$19$Initial ROU asset and lease liability$127,486$ 5 2016, and was engaged in medical related consulting services for customers. Due to the winding down of the medical relatedconsulting services in 2022, the Company decided to cease all operations of Avalon Shanghai and no longer has any material revenues or expenses in Avalon Shanghai. As a result, Avalon Shanghai is no longer an operating entity.On February 7, 2017, the Company formed Avalon RT 9 Properties, LLC (“Avalon RT 9”), a New Jersey limited liability company. OnMay 5, 2017, Avalon RT 9 purchased a real property located in Township of Freehold, County of Monmouth, State of New Jersey,having a street address of 4400 Route 9 South, Freehold, NJ 07728. This property was purchased to serve as the Company’s world-wide headquarters for all corporate administration and operations. In addition, the property generates rental income. Avalon RT 9 owns (“Arbele Biotherapeutics”) owns40% of Avactis. Avactis owns100% of the capital stock of Avactis Nanjing Biosciences Ltd., acompany incorporated in the PRC on May 8, 2020 (“Avactis Nanjing”), which only owns a patent and is not considered an operatingentity. Currently, Avactis and Avactis Nanjing are dormant and are in process of being dissolved. Q&A Distribution is engaged in distribution of KetoAir device. Details of the Company’s subsidiaries which are included in these condensed consolidated financial statements as of March 31, 2025are as follows:Name of SubsidiaryPlace and Dateof IncorporationPercentage ofOwnershipPrincipal ActivitiesAvalon Healthcare System,Delaware May100% held byHolding company for payroll and other expenses Technology Co., Ltd.(“Avalon Shanghai”)PRC April 29,2016AHS Inc. (“Genexosome”) Avactis Biosciences Inc.(“Avactis”) Avactis Nanjing BiosciencesLtd. (“Avactis Nanjing”)PRC May 8,2020100% held byAvactisDormant; in process of being dissolvedAvalon Laboratory Services,DelawareOctober 14,100% held byALBTNo current activities to report; dormant NOTE 2 –BASIS OF PRESENTATION AND GOING CONCERN CONDITIONBasis of Presentation The Company’s condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All significantintercompany accounts and transactions have been eliminated in consolidation. with U.S. GAAP have been condensed or omitted. These condensed consolidated financial statements should be read in conjunctionwith the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 31, 2025. 7 Going Concern Company is currently marketing the Keto Air breathalyzer device and plans to develop additional diagnostic uses of the breathalyzertechnology. In addition, the Company owns commercial real estate that houses its headquarters in Freehold, New Jersey. Thesecondensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which As reflected in the accompanying condensed consolidated financial statements, the Company had a working capital deficit ofapproximately $11,655,000at March 31, 2025 and had incurred recurring net losses and generated negative cash flow from operating The Company has a limited operating history and its continued growth is dependent upon the continuation of generating rental revenuefrom its income-producing real estate property in New Jersey, generating revenue for selling of Keto Air, and obtaining additional cannot be projected to cover the operating expenses for the next twelve months from the release date of this report. These matters raisesubstantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a goingconcern is dependent on the Company’s ability to raise additional capital, implement its business plan, and generate significant cash balance or report profitable operations or to continue as a going concern. The Comp